We have previously suggested that
ketone body metabolism is critical for
tumor progression and
metastasis. Here, using a co-culture system employing human
breast cancer cells (MCF7) and hTERT-immortalized fibroblasts, we provide new evidence to directly support this hypothesis. More specifically, we show that the
enzymes required for
ketone body production are highly upregulated within cancer-associated fibroblasts. This appears to be mechanistically controlled by the stromal expression of
caveolin-1 (Cav-1) and/or serum
starvation. In addition, treatment with
ketone bodies (such as 3-hydroxy-
butyrate, and/or butanediol) is sufficient to drive mitochondrial biogenesis in human
breast cancer cells. This observation was also validated by unbiased proteomic analysis. Interestingly, an MCT1 inhibitor was sufficient to block the onset of mitochondrial biogenesis in human
breast cancer cells, suggesting a possible avenue for anticancer
therapy. Finally, using human
breast cancer tumor samples, we directly confirmed that the
enzymes associated with
ketone body production (HMGCS2, HMGCL and BDH1) were preferentially expressed in the
tumor stroma. Conversely,
enzymes associated with
ketone re-utilization (ACAT1) and mitochondrial biogenesis (HSP60) were selectively associated with the epithelial
tumor cell compartment. Our current findings are consistent with the "two-compartment
tumor metabolism" model. Furthermore, they suggest that we should target
ketone body metabolism as a new area for
drug discovery, for the prevention and treatment of human
cancers.